Sanelli Pina C, Deshmukh Monica, Ougorets Igor, Caiati Rachael, Heier Linda A
Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, 520 E 70th St., Starr Pavilion-630, New York, NY 10021, USA.
AJR Am J Roentgenol. 2004 Dec;183(6):1829-34. doi: 10.2214/ajr.183.6.01831829.
Our aim was to determine the safety and feasibility of using a central venous catheter for rapid contrast injections during CT.
An in vitro experiment was performed using a 7-French Arrow-Howes multilumen central venous catheter. Each catheter port was tested by varying contrast agent flow rates delivered by a power injector. Contrast media specifications were kept similar to routine clinical practice. The in vivo experiment included 104 cases in which rapid contrast injections, 3.0-5.0 mL/sec, were delivered through a central venous catheter for dynamic CT examinations. Patient monitoring for early complications of contrast extravasation, cardiac arrhythmia, and allergic reactions was performed. Contrast injections were monitored for pressure limitation, automatic flow-rate adjustment, and catheter injury. Chart review was performed for delayed complications of mediastinal hematoma, infection, or catheter malfunction.
During the in vitro experiment, all desired flow rates, 3.0-9.9 mL/sec, could be delivered through the central venous catheter with no catheter injury. No immediate or early patient or catheter complications were observed during the in vivo experiment. Follow-up evaluation revealed that 18 blood cultures and one catheter culture were positive for bacterial growth. In a subgroup of 43 patients, five contrast injections were pressure-limited by the power injector, and only one had the flow rate automatically adjusted to 3.6 mL/sec from 4.0 mL/sec.
Rapid contrast injection rates, at 3.0-5.0 mL/sec, through the Arrow-Howes multilumen central venous catheter are feasible and safe in the clinical setting. However, a strict protocol should be followed to avoid possible serious complications.
我们的目的是确定在CT检查期间使用中心静脉导管进行快速造影剂注射的安全性和可行性。
使用7F Arrow-Howes多腔中心静脉导管进行体外实验。通过动力注射器改变造影剂流速,对每个导管端口进行测试。造影剂规格与常规临床实践保持相似。体内实验包括104例通过中心静脉导管进行快速造影剂注射(3.0 - 5.0 mL/秒)以进行动态CT检查的病例。对患者进行监测,观察造影剂外渗、心律失常和过敏反应等早期并发症。对造影剂注射进行压力限制、自动流速调整和导管损伤监测。对纵隔血肿、感染或导管故障等延迟并发症进行病历审查。
在体外实验中,所有期望的流速(3.0 - 9.9 mL/秒)都可以通过中心静脉导管输送,且无导管损伤。在体内实验中未观察到即时或早期的患者或导管并发症。随访评估显示,18份血培养和1份导管培养细菌生长呈阳性。在43例患者的亚组中,5次造影剂注射被动力注射器限制压力,只有1次流速从4.0 mL/秒自动调整至3.6 mL/秒。
在临床环境中,通过Arrow-Howes多腔中心静脉导管以3.0 - 5.0 mL/秒的速率进行快速造影剂注射是可行且安全的。然而,应遵循严格的方案以避免可能的严重并发症。